The cost-effectiveness of Herceptin® in adjuvant setting:: The HerA trial

被引：0
|
作者：
Neyt, M
Cocquyt, V
Albrecht, J
机构：
[1] State Univ Ghent, B-9000 Ghent, Belgium
[2] State Univ Ghent Hosp, B-9000 Ghent, Belgium
来源：
VALUE IN HEALTH | 2005年 / 8卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)62915-4
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：346 / 346
页数：1
相关论文
共 50 条
  • [31] LOVASTATIN IN PRAVASTATIN COMPARATIVE TRIAL - COST-EFFECTIVENESS
    FARBSTEIN, S
    AMERICAN JOURNAL OF CARDIOLOGY, 1994, 73 (05): : 417 - 417
  • [32] Approach to cost-effectiveness assessment in the MADIT trial
    Mushlin, AI
    Zwanziger, J
    Gajary, E
    Andrews, M
    Marron, R
    AMERICAN JOURNAL OF CARDIOLOGY, 1997, 80 : F33 - F41
  • [33] Cost, Effectiveness, and Cost-Effectiveness
    Diamond, George A.
    Kaul, Sanjay
    CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2009, 2 (01): : 49 - 54
  • [34] IMPACT OF STRUCTURAL ASSUMPTIONS ON COST-EFFECTIVENESS OUTCOMES: TOWARDS A STANDARDIZED COST-EFFECTIVENESS MODEL FOR ADJUVANT BREAST CANCER THERAPIES
    Frederix, G. W.
    Van Hasselt, J. G.
    Schellens, J. H.
    Hovels, A. M.
    Huitema, A. D.
    Raaijmakers, J. A.
    Severens, J.
    VALUE IN HEALTH, 2012, 15 (07) : A282 - A283
  • [35] An economic evaluation of Herceptin® in adjuvant setting:: The Breast Cancer International Research Group 006 trial
    Neyt, M
    Albrecht, J
    Cocquyt, V
    ANNALS OF ONCOLOGY, 2006, 17 (03) : 381 - 390
  • [36] Cost-effectiveness of adjuvant chemotherapy for stage III colon cancer in the South African public healthcare setting.
    Pumpalova, Yoanna S.
    Rogers, Alexandra M.
    Tan, Sarah Xinhui
    Herbst, Candice-Lee
    Ruff, Paul
    Neugut, Alfred I.
    Hur, Chin
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [37] The model-based cost-effectiveness analysis of 1-year adjuvant trastuzumab treatment: based on 2-year follow-up HERA trial data
    Takeru Shiroiwa
    Takashi Fukuda
    Kojiro Shimozuma
    Yasuo Ohashi
    Kiichiro Tsutani
    Breast Cancer Research and Treatment, 2008, 109 : 559 - 566
  • [38] The model-based cost-effectiveness analysis of 1-year adjuvant trastuzumab treatment: based on 2-year follow-up HERA trial data
    Shiroiwa, Takeru
    Fukuda, Takashi
    Shimozuma, Kojiro
    Ohashi, Yasuo
    Tsutani, Kiichiro
    BREAST CANCER RESEARCH AND TREATMENT, 2008, 109 (03) : 559 - 566
  • [39] Cost-effectiveness of adjuvant radiotherapy in intermediate risk endometrial cancer
    Rankins, N. Calloway
    Secord, A. Alvarez
    Jewell, E.
    Havrilesky, L. J.
    Soper, J. T.
    Myers, E.
    GYNECOLOGIC ONCOLOGY, 2007, 106 (02) : 388 - 393
  • [40] The cost-effectiveness issue of adjuvant trastuzumab in early breast cancer
    Norum, Jan
    EXPERT OPINION ON PHARMACOTHERAPY, 2006, 7 (12) : 1617 - 1625
12345